General Information of Drug (ID: DR1260)
Drug Name
WSM-3978G
Synonyms
Perhexilene; Perhexilina; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum; Perhexilinum [INN-Latin]; perhexilline; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine; 2-[2,2-DICYCLOHEXYLETHYL]PIPERIDINE MALEATE SALT; 39648-47-0; 39648-48-1; 6621-47-2; CHEBI:35553; CHEMBL75880; EINECS 229-569-5; EINECS 252-426-3; CYXKNKQEMFBLER-UHFFFAOYSA-N; PERHEXILINE; EINECS 254-558-7; EINECS 254-559-2; Piperidine, 2-(2,2-dicyclohexylethyl)-
Indication Hypertrophic cardiomyopathy [ICD11: BC43] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 277.5 Topological Polar Surface Area 12
Heavy Atom Count 20 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 1
Cross-matching ID
PubChem CID
4746
PubChem SID
7703131 ; 8152912 ; 10532068 ; 11335717 ; 11360956 ; 11362767 ; 11365329 ; 11367891 ; 11372717 ; 11373824 ; 11376053 ; 11461928 ; 11466314 ; 11467434 ; 11485094 ; 11486147 ; 11489355 ; 11491394 ; 11491988 ; 11493827 ; 11533619 ; 14848632 ; 29223832 ; 46504471 ; 47588963 ; 47588964 ; 47662249 ; 47810720 ; 47810721 ; 47810722 ; 47885377 ; 48184966 ; 48416398 ; 49698937 ; 50065034 ; 53788212 ; 57288805 ; 78120409 ; 96025027 ; 103274161 ; 103858531 ; 104011326 ; 104307310 ; 124883588 ; 125823713 ; 127697988 ; 134338231 ; 134988277 ; 135265378 ; 135266783
ChEBI ID
ChEBI:35553
CAS Number
6621-47-2
TTD Drug ID
D00SBN
Formula
C19H35N
Canonical SMILES
C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
InChI
1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
InChIKey
CYXKNKQEMFBLER-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Cis-Hydroxy Perhexiline DM006028
131769924
Oxidation - Hydrolyzationn 1 [2]
Monohydroxyperhexiline DM006029
46781856
Oxidation - Hydrolyzationn 1 [2]
Trans-hydroxyperhexilline DM006030
434122669
Oxidation - Aliphatic hydroxylation 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006490 WSM-3978G Cis-Hydroxy Perhexiline Oxidation - Hydrolyzationn CYP3A4 ... [2]
MR006491 WSM-3978G Monohydroxyperhexiline Oxidation - Hydrolyzationn CYP3A4 ... [2]
MR006492 WSM-3978G Trans-hydroxyperhexilline Oxidation - Aliphatic hydroxylation CYP3A4 ... [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2B6 (CYP2B6) DME0020 Homo sapiens
CP2B6_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 ClinicalTrials.gov (NCT02431221) Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure.
2 CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.